We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Sandoz’s Ziextenzo as 24th Biosimilar
FDA Approves Sandoz’s Ziextenzo as 24th Biosimilar
The FDA on Tuesday approved Sandoz’s Ziextenzo (pegfilgrastim-bmez), marking the agency’s 24th biosimilar approval and the third biosimilar of Amgen’s Neulasta.